SCHEMBL2348780

SCHEMBL2348780

O=C(O)c1nccc(Cl)c1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.44
ASPH Q12797 3/20 0.44
KDM8 Q8N371 3/20 0.44
ALDH1A1 P00352 4/20 0.42
MAPT P10636 3/20 0.42
CYP3A4 P08684 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
BLM P54132 1/20 0.42
AGER Q15109 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
KMO O15229 6/20 0.40
CYP1A2 P05177 1/20 0.38
KDM5A P29375 2/20 0.38
KDM4C Q9H3R0 2/20 0.38
LMNA P02545 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5818329 0.79 KDM4E (0.47) KDM4EASPHKDM8ALDH1A1MAPT
SCHEMBL439545 0.79 KDM4E (0.47) KDM4EASPHKDM8ALDH1A1MAPT
SCHEMBL2339609 0.78 L3MBTL1 (0.45) KDM4EALDH1A1ALOX15NPSR1L3MBTL1
SCHEMBL29683329 0.78 KDM4E (0.46) KDM4EASPHKDM8ALDH1A1MAPT
SCHEMBL6903612 0.78 KDM4E (0.50) KDM4EASPHKDM8ALDH1A1MAPT
SCHEMBL2238874 0.78 DPP4 (0.47) KDM4EASPHKDM8ALDH1A1MAPT
SCHEMBL2878004 0.78 KDM4E (0.60) KDM4EASPHKDM8ALDH1A1MAPT
SCHEMBL31500594 0.78 DPP4 (0.47) KDM4EASPHKDM8ALDH1A1MAPT
SCHEMBL30991615 0.78 KDM4E (0.46) KDM4EASPHKDM8ALDH1A1MAPT
SCHEMBL28177119 0.76 KDM4E (0.53) KDM4EASPHKDM8ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104926788-B Substituted piperidine analog derivative, the pharmaceutical composition containing it and its application in antitumor 浙江大学 2018-08-28 CN disclosed
EP-1498413-B1 4-Aminopicolinates and their use as herbicides DOW AGROSCIENCES LLC (US) 2011-08-31 EP disclosed
EP-2187893-A2 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS Anacor Pharmaceuticals, Inc. (US) 2010-05-26 EP disclosed
WO-2009111676-A2 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, INC (US) 2009-09-11 WO disclosed
EP-1246802-B1 4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2007-03-14 EP disclosed
CN-1281591-C 4-aminopyridinecarboxylates and their use as herbicides DOW AGROSCIENCES LLC (US) 2006-10-25 CN disclosed
EP-1498413-A1 4-Aminopicolinates and their use as herbicides Dow AgroSciences LLC (US) 2005-01-19 EP disclosed
CN-1416419-A 4-aminopyridinecarboxylates and their use as herbicides DOW AGROSCIENCES LLC (US) 2003-05-07 CN disclosed
EP-1246802-A1 4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES Dow Agrosciences LLC (US) 2002-10-09 EP disclosed
US-20010047099-A1 4-aminopicolinates and their use as herbicides DOW AGROSCIENCES LLC 2001-11-29 US disclosed
US-6297197-B1 DEMONSTRATING A BROAD SPECTRUM OF WEED CONTROL. DOW AGROSCIENCES LLC 2001-10-02 US disclosed
WO-2001051468-A1 4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047099-A1 4-aminopicolinates and their use as herbicides AADAT, ABAT, DDT KDM4E 668/4885ASPH 245/4885KDM8 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.